CeNeRx Biophrama, a startup focused on central nervous systems disorders, has named Atul Pande, MD, as its chief medical officer.
Pande will be tasked with leading CeNeRx research and development efforts.
He most recently served as vice president for neurosciences at Pfizer. He has a total of 13 years of experience, having also worked for Eli Lilly and Parke-Davis. At Pfizer, he led development of a new drug for the treatment of neuropathic pain and epilepsy.
CeNeRx recently closed on $18.5 million in financing.